With money flowing, Pliant Therapeutics heads to public well

Fresh off raising a $100 million Series C and sending their second compound into the clinic, Pliant Therapeutics is headed for Wall Street.

The South San Francisco-based biotech filed this morning for an $86 million IPO. The money will help fund clinical development of their lead program for a rare lung disease and rare liver disease and boost preclinical research for oncology and muscular dystrophy.